Since its inception four years ago, Tetraphase has developed a strong pipeline with a lead broad spectrum candidate in Phase 2 clinical trials, and two other differentiated candidates poised to enter the clinic in the first half of 2011. Importantly, all three of Tetraphase’s pipeline antibiotics offer significant differentiation from drugs that are currently on the market or in development by other companies.

Tetraphase Pipeline

TP-434 
A novel antibiotic, TP-434 has been shown to be effective against a majority of gram-negative multidrug-resistant (MDR) pathogens in preclinical studies. In Phase 1 studies, TP-434 was well tolerated, demonstrating an acceptable safety profile and excellent exposure.

TP-434 is ideally suited as a broad spectrum intravenous (IV) antibiotic with potential for oral stepdown for empiric treatment of severe and life-threatening bacterial infections. It has the potential to be used as a once-daily monotherapy capable of treating the majority of MDR gram-negative pathogens. TP-434 also offers potent, broad spectrum coverage of other serious and MDR gram-positive, anaerobic, and atypical pathogens.

Tetraphase is continuing to demonstrate TP-434’s differentiated profile in a Phase 2 study to assess the treatment of community-acquired complicated intra-abdominal infections (cIAIs) and via further planned studies with an oral formulation.

TP-2758 
Novel antibiotic TP-2758 is in development as an IV/oral compound specifically targeted as empiric monotherapy in complicated urinary tract infections (cUTIs). Tetraphase anticipates initiating Phase 1 trials with TP-2758 during the first half of 2011.

cUTI represents a category of bacterial infections with a high incidence of gram-negative pathogens. A rise in infections involving difficult-to-treat, resistant gram-negative pathogens has severely limited available treatment options, especially with an oral stepdown option.

TP-834 
TP-834 is in preclinical development for treatment of moderate-to-severe community-acquired bacterial pneumonia (CABP) with IV/oral administration. TP-834 will be developed as a monotherapy with once-daily dosing targeting key CABP pathogens, including penicillin- and fluoroquinolone-resistant organisms and atypicals. Tetraphase has demonstrated that TP-834 has excellent in vitro potency and in vivo efficacy. The company anticipates initiating Phase 1 trials with TP-834 in the second half of 2011.

Other Assets 
Tetraphase’s proprietary drug engine, which has produced more than 2,300 proprietary compounds with novel molecular structures, continues to offer great potential for creating additional products with significant commercial value.